-
Randomized Controlled Trial
Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial.
- Anna A Ahimastos, Adam Lawler, Christopher M Reid, Peter A Blombery, and Bronwyn A Kingwell.
- Baker Heart Research Institute, Alfred Hospital, and Monash University, Melbourne, Victoria, Australia.
- Ann. Intern. Med. 2006 May 2;144(9):660-4.
BackgroundPeripheral arterial disease (PAD) affects up to 12% of adults older than 50 years of age. Conventional therapies have only modest effects in improving symptoms.ObjectiveTo examine the effects of angiotensin-converting enzyme inhibition on walking ability in patients with PAD.DesignRandomized, double-blind, placebo-controlled trial initiated in March 2003 and completed in January 2005.SettingThe Alfred Hospital, Melbourne, Australia.Participants40 older adults with symptomatic PAD and no history of diabetes or hypertension.Intervention10 mg of ramipril (n = 20) or placebo (n = 20) once daily for 24 weeks. All patients completed the trial.MeasurementsPain-free and maximum walking time were recorded during a standard treadmill test, and the standard Walking Impairment Questionnaire was administered.ResultsAfter adjustment for the baseline pain-free walking time, mean pain-free walking time after ramipril treatment was 227 seconds (95% CI, 175 seconds to 278 seconds; P < 0.001) longer than that after placebo treatment. Similarly, maximum walking time improved by 451 seconds in the ramipril group (CI, 367 seconds to 536 seconds; P < 0.001) but did not change in the placebo group. Ramipril improved the Walking Impairment Questionnaire median distance score from 5% (range, 1% to 39%) to 21% (range, 12% to 58%; P < 0.001), speed score from 3% (range, 3% to 39%) to 18% (range, 8% to 50%; P < 0.001), and stair-climbing score from 17% (range, 4% to 80%) to 67% (range, 38% to 88%; P < 0.001). No adverse events were reported.LimitationsThe sample size is modest, and the strict inclusion criteria limit the applicability of the results to patients with claudication and infrainguinal disease and those without diabetes.ConclusionRamipril improved pain-free and maximum walking time in some adults with symptomatic PAD.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.